Status: Recruiting
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 50+Biological sex: AllType: InterventionalSponsor: Skyline Therapeutics (US) Inc.Updated: Jan 9, 2025Locations: 9
Eligibility criteria
Voluntary and able to sign a dated ICF prior to any study-related procedures and... [+4]
Any active intraocular or periocular infection or active intraocular inflammatio... [+5]